<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SCANDONEST PLAIN- mepivacaine hydrochloride injection, solution </strong><br>Novocol Pharmaceutical of Canada, Inc.<br></p></div>
<h1>Scandonest 3% Plain <br>(Mepivacaine Hydrochloride Injection, USP) <br>Scandonest 2% L (with Levonordefrin 1:20,000)<br>(Mepivacaine Hydrochloride and Levonordefrin Injection, USP)<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>THESE SOLUTIONS ARE INTENDED FOR DENTAL USE ONLY.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Mepivacaine Hydrochloride, a tertiary amine used as a local anesthetic, is 1-methyl-2', 6' -  						pipecoloxylidide monohydrochloride with the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7215f107-d1ca-466d-8f4b-f86e5249d39b&amp;name=mepi-01.jpg"></div>
<p>It is a white, crystalline, odorless powder soluble in water, but very resistant to both acid and  						alkaline hydrolysis.</p>
<p>Levonordefrin, a sympathomimetic amine used as a vasoconstrictor in local anesthetic solution,  						is (-)-<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7215f107-d1ca-466d-8f4b-f86e5249d39b&amp;name=mepi-04.jpg">-(1-Aminoethyl)-3, 4-dihydroxybenzyl  						alcohol with the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7215f107-d1ca-466d-8f4b-f86e5249d39b&amp;name=mepi-02.jpg"></div>
<p>It is a white or buff-colored crystalline solid, freely soluble in aqueous solutions of mineral acids,  						but practically insoluble in water;<br><span class="Bold">DENTAL CARTRIDGES MAY NOT BE  						AUTOCLAVED.</span></p>
<p>SCANDONEST 3% Plain (mepivacaine hydrochloride injection 3%) and SCANDONEST 2% L (mepivacaine hydrochloride 2% with levonordefrin  						1:20,000 injection are sterile solutions for injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3"></a><p></p>
<h1>COMPOSITION</h1>
<table width="100%">
<col align="left" valign="top" width="75%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="13%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="2">CARTRIDGE</th>
</tr>
<tr class="Last">
<th align="left">Each mL contains:</th>
<th align="center">2%</th>
<th align="center">3%</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">  Mepivacaine Hydrochloride</td>
<td align="center">20 mg</td>
<td align="center">30 mg</td>
</tr>
<tr>
<td align="left">  Levonordefrin</td>
<td align="center">0.05 mg</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left">  Sodium Chloride</td>
<td align="center">4 mg</td>
<td align="center">6 mg</td>
</tr>
<tr>
<td align="left">  Potassium metabisulfite</td>
<td align="center">1.2 mg</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left">  Edetate disodium</td>
<td align="center">0.25 mg</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left">  Sodium Hydroxide q.s. ad pH; Hydrochloric Acid</td>
<td align="center">0.5 mg</td>
<td align="center">-</td>
</tr>
<tr>
<td align="left">  Water For Injection, qs. ad.</td>
<td align="center">1 mL</td>
<td align="center">1 mL</td>
</tr>
<tr>
<td align="left">  The pH of the 2% cartridge solution is adjusted between 3.3 and 5.5 with NaOH.</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  The pH of the 3% cartridge solution is adjusted between 4.5 and 6.8 with NaOH.</td>
<td align="center"></td>
<td align="center"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">SCANDONEST stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia.</p>
<p>SCANDONEST is rapidly metabolized, with only a small percentage of the anesthetic (5 to 10 percent) being excreted unchanged in the urine. SCANDONEST because of its amide structure, is not detoxified by the circulating plasma esterases. The liver is the principal site of metabolism, with over 50 percent of the administered dose being excreted into the bile as metabolites. Most of the metabolized Mepivacaine is probably resorbed in the intestine and then excreted into the urine since only a small percentage is found in the feces. The principal route of excretion is via the kidney. Most of the anesthetic and its metabolites are eliminated within 30 hours. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of Mepivacaine have been identified from adult humans: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2', 6' - pipecoloxylidide).</p>
<p>The onset of action is rapid (30 to 120 seconds in the upper jaw; 1 to 4 minutes in the lower jaw) and SCANDONEST 3% Plain will<span class="Bold"> ordinarily </span>provide operating anesthesia of<span class="Bold"> 20 minutes </span>in the<span class="Bold"> upper jaw </span>and<span class="Bold"> 40 minutes </span>in the<span class="Bold"> lower jaw</span>.</p>
<p>SCANDONEST 2% L with Levonordefrin 1:20,000 provides anesthesia of longer duration for more prolonged procedures,<span class="Bold"> 1 hour to 2.5 hours </span>in the<span class="Bold"> upper jaw </span>and<span class="Bold"> 2.5 hours to 5.5 hours </span>in the<span class="Bold"> lower jaw.</span></p>
<p>SCANDONEST does not ordinarily produce irritation or tissue damage.</p>
<p>Levonordefrin is a sympathomimetic amine used as a vasoconstrictor in local anesthetic solutions. It has pharmacologic activity similar to that of Epinephrine but it is more stable than Epinephrine. In equal concentrations, Levonordefrin is less potent than Epinephrine in raising blood pressure, and as a vasoconstrictor.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Mepivacaine is indicated for production of local anesthesia for dental procedures by infiltration or nerve block in adults and pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contrain"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">SCANDONEST is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to amide-type local anesthetics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE IMMEDIATELY AVAILABLE. (See <a href="#AR">ADVERSE REACTIONS</a>).</p>
<p>Reactions resulting in fatality have occurred on rare occasions with the use of local anesthetics, even in the absence of a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p>Fatalities may occur with use of local anesthetics in the head and neck region as the result of retrograde arterial flow to vital CNS areas even when maximum recommended doses are observed. The practitioner should be alert to early evidence of alteration in sensorium or vital signs.</p>
<p>The solution which contains a vasoconstrictor (SCANDONEST 2% L) should be used with extreme caution for patients whose medical history and physical evaluation suggest the existence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">arteriosclerotic heart disease</span>, cerebral <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">vascular insufficiency</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, etc.</p>
<p>The solution which contains a vasoconstrictor (SCANDONEST 2% L) also contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people. SCANDONEST 3% Plain is SULFITE FREE.</p>
<p><span class="Bold">SCANDONEST, along with other local anesthetics, is capable of producing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>. The clinical signs of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> are <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the nail beds and lips, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. If <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> does not respond to administration of oxygen, administration of methylene blue intravenously 1-2 mg/kg body weight over a 5 minute period is recommended.</span></p>
<p>The American Heart Association has made the following recommendations regarding the use of local anesthetics with vasoconstrictors in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>: "Vasoconstrictor agents should be used in local anesthesia solutions during dental practice only when it is clear that the procedure will be shortened or the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> rendered more profound. When a vasoconstrictor is indicated, extreme care should be taken to avoid intravascular injection. The minimum possible amount of vasoconstrictor should be used." (Kaplan, EL, editor: Cardiovascular disease in dental practice, Dallas 1986, American Heart Association.)</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">The safety and effectiveness of Mepivacaine depend upon proper dosage, correct technique, adequate precautions, and readiness for emergencies.</p>
<p>The lowest dose that results in effective anesthesia should be used to avoid high plasma levels and possible adverse effects. Injection of repeated doses of Mepivacaine may cause significant increases in blood levels with each repeated dose due to slow accumulation of the drug or its metabolites, or due to slower metabolic degradation than normal.</p>
<p>Tolerance varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their weight and physical status.</p>
<p>Mepivacaine should be used with caution in patients with a history of severe disturbances of cardiac rhythm or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.</p>
<p>INJECTIONS SHOULD ALWAYS BE MADE SLOWLY WITH <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">ASPIRATION</span> TO AVOID INTRAVASCULAR INJECTION AND THEREFORE SYSTEMIC REACTION TO BOTH LOCAL ANESTHETIC AND VASOCONSTRICTOR.</p>
<p>If sedatives are employed to reduce patient <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, use reduced doses, since local anesthetic agents, like sedatives, are central nervous system depressants which in combination may have an additive effect. Young children should be given minimal doses of each agent.</p>
<p>Changes in sensorium such as excitation, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may be early indications of a high blood level of the drug and may occur following inadvertent intravascular administration or rapid absorption of Mepivacaine.</p>
<p>Local anesthetic procedures should be used with caution when there is <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and/or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> in the region of the proposed injection.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">The patient should be cautioned against <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> and possibility of biting <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> should the patient attempt to eat or chew gum prior to return of sensation.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.2"></a><p></p>
<h2>Clinically Significant Drug Interactions</h2>
<p class="First">The administration of local anesthetic solutions containing vasopressors, such as Levonordefrin, Epinephrine or Norepinephrine, to patients receiving tricyclic antidepressants or monoamine oxidase inhibitors<span class="Italics"> may </span>produce severe, prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>.</p>
<p>Phenothiazines and butyrophenones may reduce or reverse the pressor effect of Epinephrine.</p>
<p>Solutions containing a vasoconstrictor should be used cautiously in the presence of disease which may adversely affect the patient's cardiovascular system. Serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur if preparations containing a vasoconstrictor are employed in patients during or following the administration of potent inhalation anesthetics.</p>
<p>MEPIVACAINE SHOULD BE USED WITH CAUTION IN PATIENTS WITH KNOWN DRUG ALLERGIES AND SENSITIVITIES. A thorough history of the patient's prior experience with Mepivacaine or other local anesthetics as well as concomitant or recent drug use should be taken (see<a href="#contrain"> CONTRAINDICATIONS</a>). Patients allergic to methylparaben or para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross-sensitivity to agents of the amide type such as Mepivacaine. Since Mepivacaine is metabolized in the liver and excreted by the kidneys, it should be used cautiously in patients with liver and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies of Mepivacaine HCl in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies have not been conducted with this solution. It is also not known whether this solution can cause fetal harm when administered to a pregnant woman or can effect reproductive capacity. This solution should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this solution is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Great care must be exercised in adhering to safe concentrations and dosages for pedodontic administration (see<a href="#daa"> DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Reactions to SCANDONEST are characteristic of those associated with other amide-type local anesthetics. Systemic adverse reactions involving the central nervous system and the cardiovascular system usually result from high plasma levels (which may be due to excessive dosage, rapid absorption, inadvertent intravascular injection, or slow metabolic degradation), injection technique, or volume of injection.</p>
<p>A small number of reactions may result from <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, idiosyncrasy or diminished tolerance to normal dosage on the part of the patient.</p>
<p>Persistent <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> of the lips, tongue, and oral tissues have been reported with the use of mepivacaine, with slow, incomplete, or no recovery. These post-marketing events have been reported chiefly following nerve blocks in the mandible and have involved the trigeminal nerve and its branches.</p>
<p>Reactions involving the<span class="Italics"> central nervous system </span>are characterized by excitation and/or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> may occur followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, and possible <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Since <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> may be transient or absent, the first manifestations may be <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.</p>
<p><span class="Italics">Cardiovascular reactions </span>are depressant. They may be the result of direct drug effect or more commonly in dental practice, the result of <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">vasovagal reaction</span>, particularly if the patient is in the sitting position. Failure to recognize premonitory signs such as <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, feeling of faintness, changes in pulse or sensorium may result in progressive cerebral <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or serious cardiovascular catastrophe. Management consists of placing the patient in the recumbent position and administration of oxygen. Vasoactive drugs such as Ephedrine or Methoxamine may be administered intravenously.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> are rare and may occur as a result of sensitivity to the local anesthetic and are characterized by cutaneous lesions of delayed onset or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and other manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>. The detection of sensitivity by skin testing is of limited value. As with other local anesthetics, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> to Mepivacaine have occurred rarely. The reaction may be abrupt and severe and is not usually dose related. Localized puffiness and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Treatment of a patient with toxic manifestations consists of assuring and maintaining a patient airway and supporting ventilation (respiration) as required. This usually will be sufficient in the management of most reactions. Should a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span> persist despite ventilatory therapy, small increments of anticonvulsive agents may be given intravenously, such as benzodiazephine (e.g., diazepam) or ultrashort-acting barbiturates (e.g., thiopental or thiamylal) or short-acting barbiturates (e.g., pentobarbital or secobarbital). Cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may require circulatory assistance with intravenous fluids and/or vasopressor (e.g., Ephedrine) as dictated by the clinical situation. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> should be managed by conventional means.</p>
<p>IV and SC LD<span class="Sub">50</span>'s in mice for Mepivacaine Hydrochloride 3% are 33 and 258 mg/kg, respectively. The acute IV and SC LD<span class="Sub">50</span>'s in mice for Mepivacaine Hydrochloride 2% with Levonordefrin 1:20,000 are 30 and 184 mg/kg, respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="daa"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">As with all local anesthetics, the dose varies and depends upon the area to be anesthetized, the vascularity of the tissues, individual tolerance and the technique of anesthesia. The lowest dose needed to provide effective anesthesia should be administered. For specific techniques and procedures refer to standard dental manuals and textbooks.</p>
<p>For infiltration and block injections in the upper or lower jaw, the average dose of 1 cartridge will usually suffice.</p>
<p>Each cartridge contains 1.7 mL (34 mg of 2% or 51 mg of 3%).</p>
<p>5.3 cartridges (180 mg of the 2% solution or 270 mg of the 3% solution) are usually adequate to effect anesthesia of the entire oral cavity. Whenever a larger dose seems to be necessary for an extensive procedure, the maximum dose should be calculated according to the patient's weight. A dose of up to 3 mg per pound of body weight may be administered. At any single dental sitting the total dose for all injected sites should not exceed 400 mg in adults.</p>
<p>The maximum pediatric dose should be<span class="Italics"> carefully calculated.</span></p>
<p>Maximum dose for pediatric population =</p>
<table width="75%">
<col align="center" valign="top" width="47%">
<col align="left" valign="middle" width="5%">
<col align="center" valign="top" width="48%">
<tbody class="Headless"><tr class="First Last Toprule">
<td align="center">
<span class="Underline">Child's Weight (lbs.)</span><br>150</td>
<td align="left">×</td>
<td align="center">Maximum Recommended Dose<br>for Adults (400 mg)</td>
</tr></tbody>
</table>
<p>The following table, approximating these calculations, may also be used as a guide. This table is based upon a recommended maximum for larger pediatric population of 5.3 cartridges (the maximum recommended adult dose) during any single dental sitting, regardless of the pediatric patient's weight or (for 2% mepivacaine) calulated maximum amount of drug:</p>
<table width="100%">
<col align="left" valign="bottom" width="8%">
<col align="left" valign="bottom" width="31%">
<col align="left" valign="bottom" width="15%">
<col align="left" valign="bottom" width="31%">
<col align="left" valign="bottom" width="15%">
<thead>
<tr class="First"><th align="center" colspan="5">Maximum Allowable Dosage<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th></tr>
<tr>
<th align="left"></th>
<th align="left">3% Mepivacaine</th>
<th align="left"></th>
<th align="left">2% Mepivacaine</th>
<th align="left"></th>
</tr>
<tr class="Botrule">
<th align="left"></th>
<th align="left"></th>
<th align="left"></th>
<th align="left">1:20,000 Levonordefrin</th>
<th align="left"></th>
</tr>
<tr>
<th align="left"></th>
<th align="left">3 mg/lb</th>
<th align="left"></th>
<th align="left">3mg/lb</th>
<th align="left"></th>
</tr>
<tr class="Botrule">
<th align="left"></th>
<th align="left">(270 mg max.)</th>
<th align="left"></th>
<th align="left">(180 mg max.)</th>
<th align="left"></th>
</tr>
<tr class="Last">
<th align="left">Weight (lb.)</th>
<th align="left">mg</th>
<th align="left">Number of Cartridges</th>
<th align="left">mg</th>
<th align="left">Number of Cartridges</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Adapted from Malamed, Stanley F: Handbook of medical emergencies in the dental office, ed. 2, St. Louis, 1982. The C.V. Mosby Co.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">20</td>
<td align="left">60</td>
<td align="left">1.2</td>
<td align="left">60</td>
<td align="left">1.8</td>
</tr>
<tr>
<td align="left">30</td>
<td align="left">90</td>
<td align="left">1.8</td>
<td align="left">90</td>
<td align="left">2.6</td>
</tr>
<tr>
<td align="left">40</td>
<td align="left">120</td>
<td align="left">2.3</td>
<td align="left">120</td>
<td align="left">3.5</td>
</tr>
<tr>
<td align="left">50</td>
<td align="left">150</td>
<td align="left">2.9</td>
<td align="left">150</td>
<td align="left">4.4</td>
</tr>
<tr>
<td align="left">60</td>
<td align="left">180</td>
<td align="left">3.5</td>
<td align="left">180</td>
<td align="left">5.3</td>
</tr>
<tr>
<td align="left">80</td>
<td align="left">240</td>
<td align="left">4.7</td>
<td align="left">180</td>
<td align="left">5.3</td>
</tr>
<tr>
<td align="left">100</td>
<td align="left">270</td>
<td align="left">5.3</td>
<td align="left">180</td>
<td align="left">5.3</td>
</tr>
<tr class="Last">
<td align="left">120</td>
<td align="left">270</td>
<td align="left">5.3</td>
<td align="left">180</td>
<td align="left">5.3</td>
</tr>
</tbody>
</table>
<p>When using SCANDONEST for infiltration or regional block anesthesia, injection should always be made slowly and with frequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>.</p>
<p>Any unused portion of a cartridge should be discarded.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>DISINFECTION OF CARTRIDGES</h1>
<p class="First">As in the case of any cartridge, the diaphragm should be disinfected before needle puncture. The diaphragm should be thoroughly swabbed with either pure 91% isopropyl alcohol or 70% ethyl alcohol, USP, just prior to use. Many commercially available alcohol solutions contain ingredients which are injurious to container components, and therefore, should not be used. Cartridges should not be immersed in any solution.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">SCANDONEST 3% Plain; (Mepivacaine Hydrocholoride Injection USP) (NDC 12862-1098-9 and NDC 51004-1098-9) is available in cardboard boxes containing 5 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> of 10 × 1.7 mL dental cartridges, 50 per carton. SCANDONEST 2% L (Mepivacaine Hydrochloride and Levonordefrin Injection; USP) (NDC 12862-1097-8 and NDC 51004-1097-8) is available in cardboard boxes containing 5 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> of 10 × 1.7 mL dental cartridges, 50 per carton.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<p class="First">Both solutions should be stored at controlled room temperature, below 25° C (77° F).<span class="Bold"> Protect from light. </span>Do not permit to freeze. BOXES: For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap. The SCANDONEST 2% L solution should not be used if its color is pinkish or darker than slightly yellow or it contains a precipitate. Cartridge warmers should not be used with SCANDONEST products.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured for<br>SEPTODONT,<br>Louisville, CO 80027</p>
<p>by Novocol Pharmaceutical of Canada, Inc.,<br>Cambridge, Ontario, Canada N1R 6X3</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - FOR DENTAL BLOCK OR INFILTRATION ANESTHESIA</h1>
<p class="First">NDC 51004-1098-9</p>
<p><span class="Bold Italics">Scandonest 3% plain</span></p>
<p>septodont</p>
<p>Mepivacaine Hydrochloride 3% without Vasoconstrictor</p>
<p>(MEPIVACAINE HYDROCHLORIDE INJECTION, USP)</p>
<p>50 Cartridges • 1.7 mL each</p>
<p><span class="Bold">Manufactured for SEPTODONT, Louisville, CO, 80027</span></p>
<p><span class="Bold">by Novocol Pharmaceutical of Canada, Inc., Cambridge, Ontario, Canada, N1R 6X3</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1.7 mL Cartridge Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7215f107-d1ca-466d-8f4b-f86e5249d39b&amp;name=pc.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SCANDONEST PLAIN 		
					</strong><br><span class="contentTableReg">mepivacaine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51004-1098</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Mepivacaine Hydrochloride</strong> (Mepivacaine) </td>
<td class="formItem">Mepivacaine Hydrochloride</td>
<td class="formItem">30 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem">6 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51004-1098-9</td>
<td class="formItem">50  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.7 mL in 1 CARTRIDGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088387</td>
<td class="formItem">06/26/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novocol Pharmaceutical of Canada, Inc.
							(201719960)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Novocol Pharmaceutical of Canada, Inc. (201719960)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novocol Pharmaceutical of Canada, Inc.</td>
<td class="formItem"></td>
<td class="formItem">201719960</td>
<td class="formItem">MANUFACTURE(51004-1098)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9832a4f7-24d4-46f8-9099-1928c0e79b49</div>
<div>Set id: 7215f107-d1ca-466d-8f4b-f86e5249d39b</div>
<div>Version: 1</div>
<div>Effective Time: 20130626</div>
</div>
</div> <div class="DistributorName">Novocol Pharmaceutical of Canada, Inc.</div></p>
</body></html>
